公开(公告)号：CZ247798A3

公开(公告)日：1999-03-17

申请号：CZ247798

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOFFKEN HANS WOLFGANG ,  SCHWEDEN JURGEN ,  RUBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：ZA9706846B

公开(公告)日：1999-02-01

申请号：ZA9706846

申请日：1997-07-31

Applicant: BASF AG

Inventor： KOLTER KARL ,  SUBKOWSKI THOMAS ,  RADITSCH MARTIN ,  SCHEHLMANN VOLKER

IPC: A61K9/02 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/78 ,  A61K33/24 ,  A61K45/06 ,  A61K47/32 ,  A61K

CPC classification number: A61K47/32 ,  A61K9/2027 ,  A61K9/2846 ,  A61K31/78 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：ZA971107B

公开(公告)日：1998-08-11

申请号：ZA971107

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOEFFKEN HANS WOLFGANG ,  SCHWEDEN JUERGEN ,  RUEBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  C07K ,  A61K ,  C07H

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：CO4600682A1

公开(公告)日：1998-05-08

申请号：CO97006960

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  BOLLSCHWEILE CLAUS ,  HANS WOLGANG ,  RUBSAMEN KLAUS ,  FRIEDRICH THOMAS ,  SCHWEDEN JURGEN ,  SCHMIDT MARTIN

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/36 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91

Abstract: LA PRESENTE INVENCION SE REFIERE A NUEVAS TROMBIN MUTEINAS SU PREPARACION Y UTILIZACION COMO ANTIDOTO PARA LOS INHIBIDORES DE LA TROMBINA.

公开(公告)号：AU1768497A

公开(公告)日：1997-08-28

申请号：AU1768497

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOFFKEN HANS WOLFGANG ,  SCHWEDEN JURGEN ,  RUBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：DE59711600D1

公开(公告)日：2004-06-09

申请号：DE59711600

申请日：1997-07-21

Applicant: BASF AG

Inventor： KOLTER KARL ,  SUBKOWSKI THOMAS ,  RADITSCH MARTIN ,  SCHEHLMANN VOLKER

IPC: A61K9/02 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/78 ,  A61K33/24 ,  A61K45/06 ,  A61K47/32

Abstract: (Meth)acrylic acid copolymers are used to increase mucosal permeability, comonomers present being (meth)acrylic esters and/or other monomers capable of free-radical polymerization, and the (meth)acrylic acid:comonomer molar ratio varying from 99:1 to 1:99.

公开(公告)号：CZ9802477A3

公开(公告)日：1999-03-17

申请号：CZ247798

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOFFKEN HANS WOLFGANG ,  SCHWEDEN JURGEN ,  RUBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

CPC classification number: C12N9/6429 ,  A61K38/00 ,  C12Y304/21005

公开(公告)号：ZA976846B

公开(公告)日：1999-02-01

申请号：ZA976846

申请日：1997-07-31

Applicant: BASF AG

Inventor： KOLTER KARL ,  SUBKOWSKI THOMAS ,  RADITSCH MARTIN ,  SCHEHLMANN VOLKER

IPC: A61K9/02 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/78 ,  A61K33/24 ,  A61K45/06 ,  A61K47/32 ,  A61K

Abstract: (Meth)acrylic acid copolymers are used to increase mucosal permeability, comonomers present being (meth)acrylic esters and/or other monomers capable of free-radical polymerization, and the (meth)acrylic acid:comonomer molar ratio varying from 99:1 to 1:99.

公开(公告)号：NO983677D0

公开(公告)日：1998-08-11

申请号：NO983677

申请日：1998-08-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOEFFKEN HANS WOLFGANG ,  SCHWEDEN JUERGEN ,  RUEBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  C12N

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：HRP970077A2

公开(公告)日：1998-04-30

申请号：HRP970077

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOEFFKEN HANS WOLFGANG ,  SCHWEDEN JUERGEN ,  RUEBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.